I have been fortunate to have caught up with Deborah Rathjen at Sky Business (before she goes on Switzer) and at a number of presentations at my former firm. To say she is impressive would be a severe understatement, and her pathway for taking 210 forward could see it become the focal point of a major transformation. Following my first official meeting, I wrote an in-depth opinion piece for clients and have been fortunate to pick up some stock on any technical breakdown, and this one has more than a Kardashian.
Taking the PTSD route will save time and open up further opportunities. I am hoping that tension build between major pharma's and one eventually makes a hefty up-front payment. The market cap of $233m in this case would look most conservative.
Good luck to all holders, BNO could become a "feel good" story along the lines of COH should 210 prove to be a step-change in the treatment of anxiety and depression.
